Targeting Tet2, And Associated Signaling Pathways, For Amelioration Of Cognitive And Regenerative Dysfunction During Aging.

Tech ID: 32053 / UC Case 2018-082-2

Invention Novelty

This invention identifies the enzyme ten eleven translocation methylcytosine dioxygenase 2 (Tet2), and its associated signaling pathways, for the amelioration of cognitive and regenerative dysfunction during aging. This pre-clinical finding describes compositions and methods of increasing Tet2 to reverse age-related decline in adult neurogenesis and enhance cognition in all populations.

Value Proposition

The molecular mechanisms mediating cognitive and neurogenic rejuvenation remain elusive, however, this finding:

  • identifies Tet2 and associated downstream signaling pathways as targets for the amelioration of age-related cognitive and regenerative dysfunction.
  • suggests specific modulators of Tet2 as a preventative, therapeutic and/or restorative agent.
  • provides an unconventional approach for ameliorating normal aging processes and age-related cognitive disorders in the elderly, including Alzheimer’s disease and dementia.
  • shows that preventative strategies can be initiated at young adult ages.

Stage of Development

Pre-clinical

Related Materials

Patent Status

Country Type Number Dated Case
Patent Cooperation Treaty Published Application WO2019164876 08/26/2019 2018-082
 

Contact

Learn About UC TechAlerts - Save Searches and receive new technology matches

Other Information

Keywords

aging, cognition, target, therapeutic,

Categorized As